BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24217786)

  • 21. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
    Mahdi H; Maurer KA; Nutter B; Rose PG
    Int J Gynecol Cancer; 2015 Jun; 25(5):823-9. PubMed ID: 25828750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
    Fotopoulou C; Richter R; Braicu IE; Schmidt SC; Neuhaus P; Lichtenegger W; Sehouli J
    Ann Surg Oncol; 2011 Jan; 18(1):49-57. PubMed ID: 20697821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.
    Fehm T; Banys M; Rack B; Janni W; Marth C; Blassl C; Hartkopf A; Trope C; Kimmig R; Krawczyk N; Wallwiener D; Wimberger P; Kasimir-Bauer S
    Int J Gynecol Cancer; 2013 Jun; 23(5):839-45. PubMed ID: 23694981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the Surveillance, Epidemiology, and End Results database.
    McNally L; Teng NN; Kapp DS; Karam A
    Int J Gynecol Cancer; 2015 May; 25(4):607-15. PubMed ID: 25756404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
    Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.
    Hall M; Savvatis K; Nixon K; Kyrgiou M; Hariharan K; Padwick M; Owens O; Cunnea P; Campbell J; Farthing A; Stumpfle R; Vazquez I; Watson N; Krell J; Gabra H; Rustin G; Fotopoulou C
    Ann Surg Oncol; 2019 Sep; 26(9):2943-2951. PubMed ID: 31243666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer.
    Chen Y; Zhang L; Liu WX; Liu XY
    Asian Pac J Cancer Prev; 2015; 16(3):933-9. PubMed ID: 25735385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of lymph node ratio in stage IIIC epithelial ovarian cancer with node-positive in a SEER population-based study.
    Zhou J; He ZY; Li FY; Sun JY; Lin HX; Wu SG; Chen QH
    Oncotarget; 2016 Feb; 7(7):7952-9. PubMed ID: 26788911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of galectin-7 in epithelial ovarian cancer.
    Kim HJ; Jeon HK; Lee JK; Sung CO; Do IG; Choi CH; Kim TJ; Kim BG; Bae DS; Lee JW
    Anticancer Res; 2013 Apr; 33(4):1555-61. PubMed ID: 23564797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
    Tian WJ; Chi DS; Sehouli J; Tropé CG; Jiang R; Ayhan A; Cormio G; Xing Y; Breitbach GP; Braicu EI; Rabbitt CA; Oksefjell H; Fotopoulou C; Meerpohl HG; du Bois A; Berek JS; Zang RY; Harter P
    Ann Surg Oncol; 2012 Feb; 19(2):597-604. PubMed ID: 21732142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
    Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
    Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
    Benedetti Panici P; De Vivo A; Bellati F; Manci N; Perniola G; Basile S; Muzii L; Angioli R
    Ann Surg Oncol; 2007 Mar; 14(3):1136-42. PubMed ID: 17195909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
    Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC
    Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.